Show simple item record

dc.contributor.authorAmir, Eitan
dc.contributor.authorMandoky, Laszlo
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorThatcher, Nick
dc.contributor.authorKlepetko, Walter
dc.contributor.authorAnkersmit, Hendrik Jan
dc.contributor.authorReza Hoda, Mir Ali
dc.contributor.authorOstoros, Gyula
dc.contributor.authorDank, Magdolna
dc.contributor.authorDome, Balazs
dc.date.accessioned2010-08-09T12:08:20Z
dc.date.available2010-08-09T12:08:20Z
dc.date.issued2009-11
dc.identifier.citationAntivascular agents for non-small-cell lung cancer: current status and future directions. 2009, 18 (11):1667-86 Expert Opin Investig Drugsen
dc.identifier.issn1744-7658
dc.identifier.pmid19877762
dc.identifier.doi10.1517/13543780903336050
dc.identifier.urihttp://hdl.handle.net/10541/109296
dc.description.abstractBACKGROUND: Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC), survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs. OBJECTIVE: To summarize the current knowledge on antivascular therapy in patients with NSCLC. METHOD: Review of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs. RESULTS/CONCLUSION: Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC.
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshClinical Trials as Topic
dc.subject.meshDrug Delivery Systems
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshNeovascularization, Pathologic
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshTumor Markers, Biological
dc.titleAntivascular agents for non-small-cell lung cancer: current status and future directions.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Trust, Department of Medical Oncology, Manchester, UK.en
dc.identifier.journalExpert Opinion on Investigational Drugsen
html.description.abstractBACKGROUND: Despite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC), survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs. OBJECTIVE: To summarize the current knowledge on antivascular therapy in patients with NSCLC. METHOD: Review of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs. RESULTS/CONCLUSION: Bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC.


This item appears in the following Collection(s)

Show simple item record